Rhoda Au, PhD, Boston University School of Medicine, Boston, MA, introduces the Davos Alzheimer’s Collaborative (DAC), launched in January 2021 to develop precision solutions to reduce barriers to Alzheimer’s disease (AD) research for underrepresented populations across the world. The DAC aims to make AD research representative of everyone, accelerate the discovery and validation of treat novel treatment options, and make clinical care equitable to all. To do this, three major programs have been launched. Firstly, the Global Cohort Development (GCD) program has been set up to build a truly global cohort of one million people. New digital data will be collected and combined with existing cohort data to expedite biomarker and drug development. Additionally, DAC is building a global clinical trial network and technology platform that will link trial sites around the world to reduce the time and cost of clinical trials. The finally, the healthcare system preparedness arm of the project is investigating how to equip every healthcare system to deliver new innovations. It will invest in innovative approaches that lead to greater early detection and diagnosis rates. This interview took place at the Alzheimer’s Association International Conference (AAIC) 2022 in San Diego, CA.
Rhoda Au reports the following disclosures: Signant Health, Biogen, Eisai, Eversana/TauRx, GSK, Merck, Novartis, NovoNordisk.